News

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program To Pipeline, Complementing Existing Tau And Amyloid Assets With New APOE Approach
New program combines IV-delivered TRACERTM capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delive ...